Aquestive Therapeutics Q3 2026 Results: Net Loss of $16.5M, Loss Widens
Aquestive Therapeutics reported a net loss of $47.4 million for the nine months ended September 30, 2026, compared to a loss of $54.9 million in the prior year period. Total revenues increased to $35.8 million from $31.5 million, while the company recognized a $11.7 million loss on the extinguishment of debt following the redemption of its 13.5% Notes.
- Key figure
- Net loss $16.5M